Rb, a critical mediator of CDK4/6 inhibitor efficacy, determines therapeutic sensitivity, as these agents potently suppress Rb-positive tumors (e.g., breast, colorectal, and lung cancers) but show minimal activity in Rb-deficient malignancies (Iacovacci et al., 2025). This evidence concerns the gene RB1 and lung cancer.